Clinical trial NCT03552263: Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Official title: A Double-blind, Randomized and Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Mountain Sickness (AMS)
Keywords: Acute mountain sickness
Lead sponsor: Tasly Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2018-06-11
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). Specifically, for subjects in the T89 high-dose group, they will take placebo instead of T89 from Day 1 to Day 12, and take T89 on Days 13-14. The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic. Other efficacy parameters include Visual Analog Scales (VAS), exercise tolerance, blood lactate, and blood oxygen saturation that will be performed at altitude.
Primary purpose: TREATMENT

Brief summary: Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposure to low partial pressure of oxygen at high altitude that will cause a pathological effect on humans. T89 capsule is a modernized industrialized traditional Chinese herbal medicine. It is a botanical drug for oral use. In recent years, several literatures and clinical studies have showed that oral administration of T89 may provide substantial benefits in the prevention or alleviation of symptoms associated with acute mountain sickness (AMS), including nausea, vomiting, headache, dizziness, fatigue, and sleep disturbance. Such effect was also observed in a pilot clinical study recently conducted in Tibet in China.

This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent signed. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic.

Detailed description: Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposure to low partial pressure of oxygen at high altitude that will cause a pathological effect on humans. It presents a syndrome characterized by a collection of nonspecific symptoms, including headache and one of the following: gastrointestinal symptoms, fatigue and/or weakness, dizziness/light headedness or difficulty sleeping. Severity and incidence of these symptoms depend on the speed of ascent, altitude, duration of altitude exposure, physical exertion, and inherent genetic susceptibility.

T89 capsule is a modernized industrialized traditional Chinese herbal medicine. It is a botanical drug for oral use. The active substance is the water extract of Danshen (Radix Salivae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN). T89 capsule also contains Bingpian (Borneol) which may promote absorption of the active substance. In recent years, several literatures and clinical studies have showed that oral administration of T89 may provide substantial benefits in the prevention or alleviation of symptoms associated with acute mountain sickness (AMS), including nausea, vomiting, headache, dizziness, fatigue, and sleep disturbance. Such effect was also observed in a pilot clinical study recently conducted in Tibet in China.

This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent signed. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). Specifically, for subjects in the T89 high-dose group, they will take placebo instead of T89 from Day 1 to Day 12, and take T89 on Days 13-14. The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic. Other efficacy parameters include Visual Analog Scales (VAS), exercise tolerance, blood lactate, and blood oxygen saturation that will be performed at altitude. The primary efficacy endpoint is the difference in LLSS total scores on Day 16 morning (12 hours after arrival at high altitude) compared between T89 and Placebo group. A total of 120 subjects will be enrolled with approximately 40 subjects in each arm, and a minimum of 100 subjects are expected to complete the study.

Eligibility criteria: Inclusion Criteria:

1. Healthy volunteers: ages 18 - 55 years old;
2. Primary residence elevation of 1,000 ft or lower;
3. Not ascending to altitude \>10,000 ft within 4 months prior to screening;
4. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception from the time of the screening visit and throughout the study period.
5. Willing to participate voluntarily and to sign a written informed consent.

Exclusion Criteria:

1. Subjects with medical history of cardiovascular, cerebrovascular diseases or asthma;
2. Subjects with clinically significant respiratory system disease, digestive disease, mental disease, metabolic disease, acute infection or anemia;
3. Total LLSS self-assessment score and clinical assessment score is greater than 1 before ascending (Screening visit and Visit 1);
4. Blood oxygen saturation (SpO2) \<95% at sea level;
5. Subjects with abnormal renal or liver function with clinical significance (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2×upper limits of normal(ULN), Creatinine\> ULN);
6. Subjects with C reactive protein (CRP) \> ULN;
7. Subjects with primary headache;
8. Surgery or blood donation within 3 months prior to screening;
9. On treatment of any medications (including any dietary supplements)except for birth control within 14 days prior to screening and throughout the study period;
10. Contradictive to treatment of Danshen (Radix Salivae Miltiorrhizae, RSM) products;
11. Women in pregnancy or lactation period;
12. Substance abuse. Subjects with a recent history (within the last 2 years) of alcoholism or known drug dependence;
13. Participation in any other clinical trial or on an investigational drug within 30 days prior to screening;
14. A family member or relative of the study site staff;
15. Any other condition that, in the opinion of the investigator, is likely to prevent compliance with the study protocol, interfere with the assessment, or pose a safety concern if the subject participates in the study.

Primary outcomes:
measure: The LLSS self- and clinical assessments score on Day 16 morning(next morning of arrival at high altitude) between T89 and Placebo groups.
timeFrame: Day 16 morning (next morning of arrival at high altitude)
Secondary outcomes:
measure: The area under the curve (AUC) of LLSS self- and clinical assessments score in the mean LLSS score-time profile during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The total incidence of AMS evaluated by LLSS between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The mean total Visual Analog Scales (VAS) scores of headache during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The exercise tolerance (maximum wattage achieved or watts/kg and difference in watts from sea level to altitude) during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The time from the foot of the mountain to onset of AMS between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The symptom-related drop-out rate between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The total incidence of progressive diseases (e.g., HAPE, HACE, severe AMS requiring descent or treatment) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The blood oxygen saturation (SpO2) during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The LLSS self- and clinical assessments scores in subjects stratified by pooled median SpO2 value during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The blood pressure (mmHg) during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
measure: The heart rate (beats/minute) during rapid ascent (Days 15-19) between T89 and Placebo groups.
timeFrame: Day 15 to Day 19 after initiation of treatment
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Hypoxia Research Lab, UCSF Parnassus Campus, S-256
state: California
Study officials:
affiliation: Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, U.S.
name: Jeffrey W Sall, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References: